Information Provided By: 
Fly News Breaks for December 21, 2017
ZBH, VREX, LIVN, DXCM, ABMD, ABT, AXGN, HAE
Dec 21, 2017 | 07:27 EDT
Jefferies analyst Raj Denhoy calls Haemonetics (HAE), AxoGen (AXGN), Abbott (ABT) and Hologic (HOLX) his top Medical Supplies & Devices ideas to start 2018. Following a year of strong device performance in 2017, the analyst believes 2018 is "looking like more of the same." Denhoy raised his price target for Abiomed (ABMD) to $220, for Dexcom (DXCM) to $70, for Haemonetics to $68, for Hologic to $52, for LivaNova (LIVN) to $94, for Varex Imaging (VREX) to $44 and for Zimmer Biomet (ZBH) to $140. The analyst has Buy ratings on all of those stocks.
News For HAE;AXGN;ABT;ABMD;DXCM;LIVN;VREX;ZBH From the Last 2 Days
ABT
Apr 18, 2024 | 21:44 EDT
ABT
Apr 18, 2024 | 09:14 EDT
RBC Capital lowered the firm's price target on Abbott to $125 from $128 but keeps an Outperform rating on the shares. The analyst states that despite a strong Q1 with 10.8% underlying revenue and double-digit EPS growth, the stock was down 3%, which reflects sentiment on the broader MedTech space, where high expectations require a beat and raise for stocks to be rewarded. RBC maintains however that it sees upside potential for Abbott "as 2024 drivers take hold".
ABT
Apr 18, 2024 | 09:01 EDT
ABT
Apr 17, 2024 | 16:32 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
ABT
Apr 17, 2024 | 11:59 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
ABT
Apr 17, 2024 | 10:00 EDT
Says pipeline contributing at an "accelerated level." Says more opportunities vs. risks going forward. Targeting about 70 bps in gross margin improvement in FY24. Says FX challenges still remain. Says all business segments "super well aligned" to demographics, health care trends.
ABT
Apr 17, 2024 | 09:41 EDT
Unusual total active option classes on open include: Steel Dynamics (STLD), Gildan Activewear (GIL), Danaher (DHR), Altimeter Growth (GRAB), Childrens Place (PLCE), ASML (ASML), US Bancorp (USB), iShares Barclays 7 to 10 Year Treasury Bond Fund (IEF), AMC Entertainment (AMC), and Abbott (ABT).
ABT
Apr 17, 2024 | 09:16 EDT
ABT
Apr 17, 2024 | 08:56 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER - Alcoa (AA)... To see the rest of the story go to thefly.com. See Story Here
ABT
Apr 17, 2024 | 07:36 EDT
ABT
Apr 17, 2024 | 07:34 EDT
Worldwide Medical Devices sales increased 14.2% on a reported basis and 14.3% on an organic basis in the first quarter, including double-digit growth in both the U.S. and internationally.
ABT
Apr 17, 2024 | 07:33 EDT
ABT
Apr 17, 2024 | 07:32 EDT
FY24 consensus $4.59. Abbott narrowed its full-year 2024 organic sales growth guidance range, excluding COVID-19 testing-related sales, to 8.5%-10.0%, which represents an increase at the midpoint of the range. Prior view was FY24 organic sales growth, excluding COVID-19 testing-related sales, in the range of 8.0%-10.0%. FY24 revenue consensus $41.99B.
ABT
Apr 17, 2024 | 07:30 EDT
Reports Q1 revenue $10B, consensus $9.88B. "Our first-quarter results reflect a strong start to the year, and we are raising our full-year sales and EPS guidance," said Robert Ford, chairman and CEO, Abbott. "This was the fifth consecutive quarter that we delivered double-digit organic sales growth in our underlying base business, which included particularly strong results in Medical Devices and Established Pharmaceuticals."
